ACADIA Pharmaceuticals Inc.
5-HT2A SEROTONIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR USE IN REDUCING AMYLOID-BETA PEPTIDES AND ACCUMULATION OF AMYLOID PLAQUES
Last updated:
Abstract:
Described are compounds and compositions for use in methods for reducing the rate of accumulation of amyloid plaques in a subject by administering a 5-HT2A serotonin receptor inverse agonist or antagonist, or pharmaceutically acceptable salts thereof.
Status:
Application
Type:
Utility
Filling date:
16 Feb 2021
Issue date:
6 Jan 2022